Distinct Temporal Modulation of Mesenchymal Stem Cells and Empagliflozin on Renal c-Kit Cells in Diabetic Kidney Disease
Frontiers in Bioscience-Landmark · 20.07.2026 · 31 (7)
DOI: 10.31083/fbl51501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 20.07.2026. Verfasst von Gabriela Esteves de Jesus und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, SP 05653-000, Brazil. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Proto-Oncogene Proteins c-kit, Diabetic Nephropathies, Glucosides. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo/São Paulo Research Foundation, CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Coordination for the Improvement of Higher Education Personnel), CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico/National Council for Scientific and Technological Development.
Abstract (Originalsprache)
Background:Diabetic kidney disease (DKD) remains a leading cause of chronic kidney disease worldwide despite current standard therapies. c-Kit+ renal progenitor cells have been implicated in kidney repair and regeneration. We investigated whether mesenchymal stem cells (MSCs) and the sodium-glucose cotransporter-2 inhibitor empagliflozin are associated with differential modulation of intrarenal c-Kit+ cell expression in a preclinical model of DKD using BTBRob/ob mice.Methods:These BTBRob/ob mice were allocated into three groups: untreated DKD, MSC-treated DKD, and empagliflozin-treated DKD, and were compared with BTBR wild-type (WT) controls. BTBRob/ob mice received empagliflozin formulated inchow ad libitum at 25 mg/kg (Jardiance®, Boehringer Ingelheim, Ingelheim am Rhein, RP, Germany) starting at 4–5 weeks of age. MSCs (1 × 106 cells per dose) were administered intraperitoneally at 8 and 10 weeks of age. Animals were evaluated at 10, 14–15, and 18–20 weeks. Renal c-Kit gene expression was quantified by quantitative real-time PCR (qPCR), and protein expression was assessed by immunohistochemistry in the cortex, medulla, and glomeruli. Statistical analyses included mixed-effects models and two-way analysis of variance (ANOVA).Results:c-Kit expression was significantly influenced by time and treatment in both cortex and medulla. In the renal cortex, MSC therapy was associated with a transient increase in c-Kit gene expression at 14–15 weeks, followed by a reduction at 18–20 weeks. Empagliflozin predominantly modulated cortical c-Kit expression at later time points. Immunohistochemistry demonstrated higher cortical c-Kit protein expression in MSC-treated animals compared with untreated DKD mice. In the medulla, MSC-treated mice exhibited increased c-Kit expression at 14–15 weeks, which declined at 18–20 weeks. Empagliflozin had a modest effect on c-Kit expression and was associated with infrequent glomerular immunoreactivity at 14–15 weeks.Conclusions:MSC therapy and empagliflozin are associated with distinct temporal patterns of c-Kit expression in DKD. MSC treatment showed early modulation of c-Kit expression, whereas empagliflozin exhibited more delayed effects. These findings suggest that c-Kit+ cells are dynamically regulated during DKD progression. Given the absence of functional and mechanistic analyses, these results should be considered hypothesis-generating and warrant further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, SP 05653-000, Brazil.
- Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, SP 05653-000, Brazil.
- Nephrology Division, Department of Internal Medicine, University of São Paulo, São Paulo, SP 05403-900, Brazil.
- Nephrology Division, Medicine Department, Federal University of São Paulo, São Paulo, SP 04038-031, Brazil.
Förderung
- FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo/São Paulo Research Foundation
- CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Coordination for the Improvement of Higher Education Personnel)
- CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico/National Council for Scientific and Technological Development
- EFSD (European Foundation for the Study of Diabetes)
Zitieren
APA
de Jesus, G. E., de Bastos, R. M. C., Sávio-Silva, C., Beyerstedt, S., Franco, M. L., Gomes, S. A., & Rangel, É. B. (2026). Distinct Temporal Modulation of Mesenchymal Stem Cells and Empagliflozin on Renal c-Kit Cells in Diabetic Kidney Disease. Frontiers in Bioscience-Landmark, 31(7). https://doi.org/10.31083/fbl51501
Vancouver
de Jesus GE, de Bastos RMC, Sávio-Silva C, Beyerstedt S, Franco ML, Gomes SA, et al. Distinct Temporal Modulation of Mesenchymal Stem Cells and Empagliflozin on Renal c-Kit Cells in Diabetic Kidney Disease. Frontiers in Bioscience-Landmark. 2026;31(7). doi:10.31083/fbl51501
BibTeX
@article{deJesus2026,
author = {de Jesus, Gabriela Esteves and de Bastos, Rosana Maria Cardoso and Sávio-Silva, Christian and Beyerstedt, Stephany and Franco, Marcella Liciani and Gomes, Samirah Abreu and Rangel, Érika Bevilaqua},
title = {Distinct Temporal Modulation of Mesenchymal Stem Cells and Empagliflozin on Renal c-Kit Cells in Diabetic Kidney Disease},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {7},
doi = {10.31083/fbl51501}
}
EUVIMED